Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease

Brian A. Lawlor, Linda M. Bierer, Theresa M. Ryan, James Schmeidler, Peter J. Knott, Lizette L. Williams, Richard C. Mohs, Kenneth L. Davis

Research output: Contribution to journalArticlepeer-review

31 Scopus citations


Postmortem findings point to significant abnormalities in central noradrenergic function in Alzheimer's disease (AD) which may be associated with changes in peripheral markers. In this study, the relationship between the peripheral noradrenergic marker, plasma 3-methoxy-4-hydroxyphenylglycol (MHPG), and clinical symptoms was examined in 23 patients with probable AD. Basal MHPG levels correlated significantly with increased cognitive impairment (r = .58, p = .005), controlling for age, age at onset, gender, and time interval between plasma MHPG determination and cognitive testing. These results suggest that plasma MHPG increases as cognitive function in AD deteriorates, further supporting preliminary evidence for increases in noradrenergic indices in association with disease severity in AD.

Original languageEnglish
Pages (from-to)185-188
Number of pages4
JournalBiological Psychiatry
Issue number3
StatePublished - 1 Aug 1995
Externally publishedYes


  • Alzheimer's disease
  • clinical symptoms
  • plasma MHPG


Dive into the research topics of 'Plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) and clinical symptoms in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this